Zloza Laboratory

Research Overview

Zloza Laboratory

     Research Overview

     Andrew Zloza, MD, PhD

     Current Lab Members

     Lab Alumni

Our laboratory focuses on understanding the interplay between infections, cancer, and the immune system. We have discovered that non-oncogenic infections (those that do not directly cause cancer) regulate tumor occurrence and growth (in both negative and positive ways). Therefore, we strive to understand the mechanisms underlying these effects and to translate our findings toward patient therapies against cancer.

Toward this effort we have developed the autologous immune-reconstituted patient-derived xenograft (AIR-PDX) mouse model and novel biotechnologies. These allow us to conduct in vivo studies of a patient’s anti-cancer immune response in the context of that patient’s own intact tumor microenvironment, and to efficiently target our therapies to the tumor microenvironment. Our goals are to discover new cancer immunotherapies and to develop a unified theory of infection, cancer, and immunity. 

 

News and Events!

Last updated: November 3, 2017

 

NOVEMBER 2017

PUBLICATION: Our article "Nanoparticles: Augmenting Tumor Antigen Presentation for Vaccine and Immunotherapy Treatments of Cancer" has been published in Nanomedicine

 

OCTOBER 2017

PUBLICATION: Our article "Infection:  A Cause of and Cure for Cancer" has been published in Current Pharmacology Reports

 

SEPTEMBER 2017

PUBLICATION: An article summarizing the workshop that Dr. Zloza co-organized at SITC 2016 (with Marcus Bosenberg of Yale and A. Karolina Palucka of Jackson Laboratory) "Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer" has been published in the Journal for ImmunoTherapy of Cancer (JITC)!

Please join our PhD candidate, Praveen Bommareddy, as he presents "Oncolytic HSV-1 viruses as novel therapies for melanoma treatment" at the International Conference on Cancer Biology and Drug Delivery on September 19 in Philadelphia, Pennsylvania, USA -- congrats Praveen!

FUNDING: The NIH has awarded the Zloza Lab a UM1 supplement grant for the study "Validation of flow cytometry for tumor immune cells after hypothermal transport" (Project Leader: Zloza)

PUBLICATION: Our article "Oncolytic Viruses - Natural and Genetically Engineered Cancer Immunotherapies" has been published by Frontiers in Oncology

 

AUGUST 2017

PUBLICATION: Thanks to the Dr. Mark Stein (Rutgers CINJ) and our collaborators at Oncoceutics for involving us in the study "First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors" published in Clinical Cancer Research! 

 

MAY 2017

Please join our radiation oncology resident Sachin Jhawar at the annual AAI meeting Immunology 2017 on May 12th in Washington D.C. where he will present his work "Radiation Therapy and Talimogene Laherparepvec (TVEC) Synergize in the Treatment of Melanoma" for which he received a 2017 AAI Trainee Abstract Award -- congrats Sachin!

 

APRIL 2017

AWARD + FUNDING: Thank you! to the organizers of the 3rd Annual Immuno-Oncology Young Investigators’ Forum and to the Faculty Judges for my 2nd Place Award and Research Grant in the Junior Faculty Category! It was completely unexpected, but is greatly appreciated!

PUBLICATION: Thanks to the Gupta Lab (Rush University) for involving us as collaborators on the study "CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus" published in Journal of Clinical Investigation!

Dr. Zloza has been invited to present our lab's work on "Targeting Anti-viral Immune Responses to Recondition the Tumor Microenvironment" at the  3rd Annual Immuno-Oncology Young Investigators’ Forum’ Forum held on April 20-23 in Houston, Texas -- what a great honor!

 

MARCH 2017 

Please join Dr. Zloza at the 3rd Annual Immune Checkpoint Inhibitors (ICI) Meeting in Boston, MA on March 15, where he has been invited to present "Enhancing The Translatability Of Preclinical Models To Boost Translation Into The Clinic."

PUBLICATION: Thanks to the Kaufman Lab (Rutgers) for involving us in this review  "Talimogene Laherparepvec (T-VEC) as Cancer Immunotherapy" published in Personalized Medicine in Oncology!

 

FEBRUARY 2017 

Please join Dr. Zloza at the ImmunoTX Summit 2017, February 6 in San Diego, CA as he moderates the "Conditioning the Tumor Microenvironment for Immunotherapy" section and presents our work on "Harnessing Anti-Pathogen Immune Responses to Recondition the Tumor Microenvironment"

 

JANUARY 2017 

FUNDING: C. Brent Chesson (post-doctoral fellow) has been awarded a Post-Doctoral Fellowship Grant from the New Jersey Commission on Cancer Research! Congrats, Brent!

PUBLICATION: Our study “Low dose interleukin-2 (IL-2) impairs host anti-tumor immunity and inhibits therapeutic responses” conducted in collaboration with the Kaufman Lab (Rutgers) has been published in Cancer Immunology, Immunotherapy!

PUBLICATION: Thanks to the Reiser Lab (Rush University) for involving us in this collaboration: "Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease" published in Nature Medicine!

 

DECEMBER 2016

PUBLICATION: Thanks to the Lasfar Lab (Rutgers) for involving us in the study "IFN-λ: A New Inducer of Local Immunity against Cancer and Infections" published in Frontiers in Immunology.

 

NOVEMBER 2016

Please join Dr. Zloza at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD on November 10th for the workshop that he has co-organized "Workshop on Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy" as he moderates "Session I: Introduction to Models of Immunotherapy" and presents an "Overview of Patient-Derived Xenograft (PDX) Models."

 

OCTOBER 2016 

PUBLICATION: Our study “Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death” is now published in Cell Reports! This is the first in a line of very intersting discoveries we have made regarding the interaction between infections and cancer -- more to come soon!  

 

SEPTEMBER 2016

FUNDING: Our study “Autologous double-humanized mouse model for the study of Pembrolizumab” (MISP # 55542) has been funded by Merck (PI: Zloza). 

FUNDING: We been awarded research funding from Gateway For Cancer Research for our collaborative proposal with the Kaufman Lab (Rutgers) on the study “Combination Oncolytic Virus and PD-1 Blockade for Melanoma Treatment” (PI: Kaufman, Co-PI: Zloza)


 

AUGUST 2016

PUBLICATION: Thanks to the Lasfar Lab (Rutgers) for involving us on the study "Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth" published in Oncotarget!

 

JULY 2016

PUBLICATION: Thanks to the Lasfar Lab (Rutgers) for involving us on the review "IFN-λ cancer immunotherapy: new kid on the block." published in Immunotherapy!

 

MARCH 2016

PUBLICATION: Thanks to the Kaufman Lab (Rutgers) and our collaborators at Amgen for involving us in the study "Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.

 

JANUARY 2016

PUBLICATION: Thanks to the Lasfar Lab (Rutgers) for including us on the reivew "IFN-lambda therapy: current status and future perspectives" published in Drug Discovery Today!

 

SEPTEMBER 2015

PUBLICATION: Our review "Talimogene laherparepvec (T-VEC) as cancer immunotherapy" in collaboration with the Kaufman Lab (Rutgers) has been published in Drugs Today!

PUBLICATION: Our review "Oncolytic viruses: a new class of immunotherapy drugs" has been published in Nature Reviews Drug Discovery!

 

JUNE 2015

PUBLICATION: Thanks to the Rudra Lab (University of Texas-Medical Branch) for involving us in the study "Enhancing the Magnitude of Antibody Responses through Biomaterial Stereochemistry" that has been published in ACS Biomaterials Science & Engineering!

 

MAY 2015

AWARD: The American Association of Immunologists (AAI) has awarded Dr. Zloza the 2015 Chambers-eBioscience Memorial Award! Thank you for this great honor!

PUBLICATION: Our study "NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade" has been published in the Journal for Immunotherapy of Cancer!

Please join Dr. Zloza at the annual AAI meeting Immunology 2015 on May 8th in New Orleans, LA where he will present the study "Combination immunotherapy utilizing influenza infection and PD-1 blockade reduces lung melanoma tumor growth" for which he has received the  2015 Chambers-eBioscience Memorial Award!

 

APRIL 2015

PUBLICATION: Thanks to the Sun Lab (UIC) for involving us in the study "HIV Infection Leads to Redistribution of Leaky Claudin-2 in the Intestine of Humanized SCID IL-2R(-/-) Hu-PBMC Mice" published in AIDS Research and Human Retroviruses.

 

FEBRUARY 2015

WE HAVE ARRIVED! I want to thank the administration at Rutgers Cancer Institute of New Jersey and the Department of Surgery at Rutgers Robert Wood Johnson Medical School for recruiting us here! Let a new phase in our discovery of mechanisms and development of cures for cancer begin!

THANK YOU! I want to thank my friends and colleagues in the Department of Internal Medicine and Department of Immunology/Microbiology at Rush University for a life-changing experience and for all the kind wishes on our move! -- we will miss seeing you all daily!

 

Contact Us

We welcome inquiries about our research and new collaboration opportunities. Please contact us!
andrew.zloza@rutgers.edu   

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health